Hand, Foot and Mouth Disease Clinical Trial
Official title:
Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children
Hand, Foot and Mouth Disease(HFMD)is an infectious disease in infants and young children caused by enterovirus. There was a great outbreak of HFMD in China, 2008, which brought not only panic to the people, but also huge economic loss. Since 2008, HFMD has become one of the category c infectious diseases in China. Studies showed that Human Enterovirus 71 (EV71) and coxsackievirus A 16 (CVA16) are the most common reasons for this disease. And the investigators are going to develop the vaccines for this disease. There is an urgent need to know the dynamic changes of the maternal anti-EV71 and ant-CVA16 level in infants and young children. In April 2007, the investigators started a clinical trial named 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' (ClinicalTrials.gov ID: NCT01183611). In that study the investigators already built a cohort of Health Neonates, followed them and obtained the blood serum on the day 0, 30, 210 and 360 after born. So, based on the cohort and blood serum the investigators got, the investigators plan this study to retrospectively investigate their HFMD histories from birth and follow-up for another year to get the information about the incidence of HFMD. The investigators also plan to assay the maternal anti-EV71 and anti-CVA16 antibodies on the day0 and the dynamic changes of antibodies on 1st month, 7th month (day 210), 1st year (day 360) and on October, 2010.
Status | Completed |
Enrollment | 1297 |
Est. completion date | September 2011 |
Est. primary completion date | September 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 2 Years to 3 Years |
Eligibility |
Inclusion Criteria: - The subjects participated in the clinical trial named 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates'in 2007 (ClinicalTrials.gov ID: NCT01183611). - Written informed consent obtained from the parent(s) of the subject. - Subjects who the investigator believes will comply with the requirements of the protocol. Exclusion Criteria: - Neonatal jaundice requiring systemic treatment. - Major congenital defects or serious chronic illness. - Maldevelopment - Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
China | Jiangsu Provincial Center for Diseases Control and Prevention | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Province Centers for Disease Control and Prevention |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | dynamic changes of the maternal anti-EV71 | dynamic changes of the maternal anti-EV71 in infants and young children | from birth to 3 years old | No |
Secondary | dynamic changes of the maternal anti-CVA16 | dynamic changes of the maternal anti-CVA16 in infants and young children | from birth to 3 years old | No |
Secondary | incidence of HFMD | retrospectively investigate their HFMD histories from birth and follow-up for another year to get the information about the incidence of HFMD. | from birth to 3 years old | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06063057 -
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
|
Phase 1/Phase 2 | |
Completed |
NCT04133584 -
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine
|
Phase 4 | |
Completed |
NCT03241030 -
Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial
|
Phase 2 | |
Completed |
NCT03873740 -
Immunogenicity and Safety of Two Different Commercial EV71 Vaccines
|
Phase 4 | |
Completed |
NCT05637229 -
A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
|
||
Recruiting |
NCT06146088 -
Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine
|
Phase 4 | |
Active, not recruiting |
NCT06209398 -
Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine
|
Phase 4 | |
Recruiting |
NCT01145664 -
A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease
|
N/A | |
Recruiting |
NCT01175915 -
A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Completed |
NCT01182532 -
A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Completed |
NCT03281174 -
Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine
|
N/A | |
Completed |
NCT03582761 -
Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71
|
Phase 4 | |
Completed |
NCT03903926 -
Efficacy Trial of a Commercial EV71 Vaccine
|
Phase 4 | |
Completed |
NCT02001233 -
A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
|
||
Completed |
NCT03909074 -
Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months
|
Phase 3 | |
Completed |
NCT01769794 -
Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study
|
N/A | |
Recruiting |
NCT01182025 -
A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Recruiting |
NCT06263439 -
Surveillance of HFMD in Pediatric Outpatients
|
||
Not yet recruiting |
NCT05397587 -
An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell)
|
Phase 4 | |
Completed |
NCT04111432 -
Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines
|
Phase 4 |